This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Menopause
  • /
  • Autologous PRP Infusion May Restore Ovarian Functi...
Clinical trial

Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients (PRP)

Read time: 1 mins
Last updated:18th Mar 2024
Status: RECRUITING
Identifier: NCT04031456
Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients (PRP)


ClinicalTrials.gov ID: NCT04031456
Sponsor: Genesis Athens Clinic
Information provided by: Genesis Athens Clinic (Responsible Party)
Last Update Posted: 2023-02-23

Brief Summary:
Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.

Detailed Description:
This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to patients presenting with POI. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in POI patients.

Official Title:
Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients

Intervention / Treatment:
- Biological: Autologous Platelet Rich Plasma
- Biological: Placebo-Platelet Free Plasma

Category Value
Study Start (Actual) 2019-07-30
Primary Completion (Estimated) 2026-01-30
Study Completion (Estimated) 2026-07-30
Enrollment (Estimated) 100
Study Type Interventional
Phase Phase 2
Phase 3
Other Study ID Numbers
PRP- POI


View full details